Mr. Nicholas Sosiak reports

CANNARA ACHIEVES OTCQX QUALIFICATION AND ANNOUNCES RELEASE OF FISCAL Q1 2026 FINANCIAL RESULTS ON JANUARY 26, 2026

Cannara Biotech Inc. has qualified to have its common shares quoted for trading on the OTCQX Best Market (OTCQX). Cannara's common shares were previously quoted on the OTCQB Venture Market.

Effective today, Cannara's common shares will begin trading on OTCQX under the symbol LOVFF. The company's common shares will continue to be listed on the TSX Venture Exchange as well as on the Frankfurt Stock Exchange, both of which remain unchanged and unaffected by the OTCQX qualification.

"Our qualification to trade on OTCQX is a meaningful step forward in Cannara's capital markets strategy," said Nicholas Sosiak, chief financial officer of Cannara Biotech. "It increases our exposure to institutional and retail investors in the United States while reinforcing our commitment to strong governance, disclosure and disciplined growth."

Q1 2026 financial results

The company also announced it will release its financial results for the first quarter of fiscal 2026 on Monday, Jan. 26, 2026, at 7 a.m. ET. Cannara Biotech chief executive officer Zohar Krivorot and CFO Nicholas Sosiak will host an earnings webcast on Jan. 26, 2026, at 11 a.m. ET, consisting of prepared remarks followed by a live question-and-answer session.

Participants may register for the earnings webcast here or by visiting the company event section on the company's website.

Annual general and special meeting of shareholders

The company further reminds shareholders that Cannara's annual general and special meeting of shareholders is scheduled for Jan. 29, 2026, at 11 a.m. ET and will be held via live webcast on-line.

Shareholders are encouraged to vote on the matters before the meeting by proxy and to join the meeting by webcast. Those who would like to vote on matters by proxy are requested to read the notes to form of proxy and then to, complete, sign and mail the enclosed form of proxy in accordance with the instructions set out in the proxy and in the management proxy circular that have been posted on Cannara's website and filed on SEDAR+.

About Cannara Biotech Inc.

Cannara Biotech is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Quebec spanning over 1.65 million square feet, providing the company with 100,000 kilograms of potential annualized cultivation output. Leveraging Quebec's low electricity costs, Cannara's facilities produce premium-grade cannabis products at an affordable price.